Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.10 3.1% 103.00 102.00 102.80 102.80 98.00 98.10 824,503 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.5 -30.3 -22.8 - 186

4d Pharma Share Discussion Threads

Showing 12851 to 12875 of 23400 messages
Chat Pages: Latest  516  515  514  513  512  511  510  509  508  507  506  505  Older
DateSubjectAuthorDiscuss
25/10/2020
17:41
Bad batch...
rastamouse
25/10/2020
17:34
I think you should smoke less weed Rastamouse. It makes you come over all negative for some reason? #wantinlower
showmethemoneyhoney01
25/10/2020
16:43
Bredrin,Let's jus wait and see.Babylonia was not built in a day maan.Ta raas.Peace out.
rastamouse
25/10/2020
16:30
That's the spirit Rastamouse! :-)
thresholdbypass
25/10/2020
15:19
Shouldn't compare like for like as they simply aren't. Time will tell and the markets will determine the share price at any given time depending on how the company performs be it on Nasdaq, Aim or where ever. The future is bright for 4D and thats really all we need to know at this stage !
thepaddedcell
25/10/2020
14:56
What and pay 20× the current price??;-)
rastamouse
25/10/2020
14:49
I second that F3rdinand! And let's see what gives Rastamouse, in the end nobody knows of course, but I have not seen a more promising moment in a company than this one. Comparing it to other failures on Nasdaq listing not so helpfull either. You could also wait and buy when the MC is well established of course...
thresholdbypass
25/10/2020
14:48
Just a thought on the mono therapy results which Duncan mentions in a positive light numerous times now....I wonder if Merck will have seen these results already or if they will see them for the first time at the STIC conference ? It's a completely different study to Keytruda trial but we have various research programs running with Merck now....I guess it might depend wether the company would go it alone with the mono therapy (if successful) or partner on the program
bms1a3c
25/10/2020
14:38
Not saying 4D market cap should be the same as Seres. However there is a disconnect and will be corrected soon.The presentations at SITC Conference are key to provide true value. 4D pharma announces three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020.Initial immune modulation and safety data from MRx0518 neoadjuvant monotherapy trial in patients awaiting surgical resection of solid tumors.Update on safety and efficacy results of Part A of combination trial of MRx0518 and Keytruda® in patients refractory to immune checkpoint inhibitors.Further information on ongoing Part B cohort expansion phase of MRx0518 and Keytruda® combination trial.On Vox interview CEO talks about November SITC presentations & after discussing the Keytruda one, CEO says "more importantly, we'll be presenting information about our monotherapy trials"https://www.voxmarkets.co.uk/articles/4d-pharma-on-their-merger-intention-to-seek-nasdaq-listing-plus-chris-bailey-on-4-large-caps-5e542fc/
hodr
25/10/2020
14:22
I think comparing 4D's market cap with another microbiome company listed on the NASDAQ is a very worthwhile exercise! In his recent interview Duncan Peyton made it very clear that 4D are the world leaders in the field and in terms of patents and research who can disagree!This share will be valued at well over half a billion by mid January. Very exciting
f3rdinand
25/10/2020
14:14
Not entirely convinced by the responses and still refer back to my original points.I have more caution/questions but will hold back as I do not want to come across as negative on DDDD, I'm actually bullish.But find the comparison with Seres valuation unhelpful and currently unrealistic.Last comment on valuation comparison.Peace out.
rastamouse
25/10/2020
14:14
Rasta - another point to note is that Merck's Keytruda is on course to be the world's biggest selling drug by revenue in a couple of years. "GlobalData has predicted that MSD's immuno-oncology blockbuster, Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, raking in $22.2bn by 2025." 4D are trialling their MRx0518 in combination with Keytruda. And is already showing amazing results... "The disease control rate observed in part A of the study, at 42%, far exceeds the 10% threshold for success agreed with our partner MSD for the cohort expansion phase, boding well for the outcome of the ongoing Part B of the study..." As MRx0518 has almost zero side effects why wouldn't patients who take Keytruda also take MRx0518? Maybe an over-simplification, but hopefully you can see the potential here. And that's just one of the many pipelines 4D have.
someuwin
25/10/2020
14:04
As points made by someuwin and HODR show and you could have found out yourself Rastamouse, with a little less focus on prooving your own quick found caution, there is more to it than just a Nasdaq listing. But yeah, the listing will certainly provide a way way bigger pile of money that wants to invest in these type of companies. And "optimists" here are saying we are one of the most promising and leaders in the field. But it does not mean you cannot ask questions, maybe they would be received better if they did not sound so much like casting doubt
thresholdbypass
25/10/2020
13:47
Good points HODR. All said and done as long as 4Ds work benefits the human race and also investors I'm happy. Good luck to all. P.S mostly this is a good board can we keep it that way.
royalalbert
25/10/2020
13:42
I would also count Seres P3 a fail based on the response from the FDA & need to rerun as a larger trial. FDA not willing to meet Seres!Seres not going to generate revenue anytime soon with SER-109 BLA in open market.4D far more developed & robust approach to trials.See FDA correspondence https://twitter.com/lramseu/status/1320354175323176960?s=21However Seres valuation $2.69b.4D IBS trial in phase 2 was much larger than Seres phase 3.
hodr
25/10/2020
13:42
I never said "nothing is coming."I just stated that comparisons with Seres are premature and unrealistic at this moment in time.I recall the same type of hype when DDDD was 10 pounds. We all know what happened.I'm just saying realistic optimism is what is needed.Also I recommend cation to those who assume that a Nasdaq listing will automatically result in a significant re-rate in price. It simply doesn't work that way.Peace out.
rastamouse
25/10/2020
13:37
Fair point Someuwin.Informative.Thank you.
rastamouse
25/10/2020
13:31
Someuwin nice response, although I do agree with Rasta on some points. That's why peeps should always do their own research as well as reading bulletin boards.
royalalbert
25/10/2020
13:27
If you think nothing is coming (which it is), then what are you doing here Rastamouse?
thresholdbypass
25/10/2020
13:25
Seres Therapeutics don't have 'real' revenues of $36m. They aren't selling any products. The revenues are 'related party' and are mainly what Nestle is paying for their collaboration. 4D have a collaboration with Merck for which Merck are contracted to pay over £1bn on achieving certain milestones. Just a different way of recognising 'revenue' and putting valuations on collaborations. Perhaps when 4D is listed on Nasdaq we will have a deferent way of accounting for such things.
someuwin
25/10/2020
13:17
Come on TT, surely you've learnt your lesson from being over optimistic and bullish and being more measured when investing and raising relevant questions/caution from overally bullish sentiment from CEOs and BB bulls (OPTI comes to mind)..Measured and realistic approach always best.Peer comparison can also be helpful but can at times raise unrealistic value expectations.Surely TT the OPTI vs the DDDD valuation anomaly was one. DDDD crashed from 10 pounds to comparable value with OPTI.Surely everyone also recalls what happened to Bioprogress once it listed on NASDAQ??So caution is good.DDDD has some amazing potential.Peace out.
rastamouse
25/10/2020
13:07
I have had a blast enjoying the surf the last couple of weeks and glad I switched off from the price action with 4D and all nonsense that have been written here since, my 4D holding remains untouched and working as I thought it would. One thing for sure is that I have way more trust and confidence in our very experienced BOD than any of the Genius investor like these one: "1SJH 15 OCT '20 - 14:49 - 11761 OF 12629 0 2 2 NO ONE IS HOLDING THE PRICE AT £1 SOME ARE JUST BUYING BUT I SEE NO OTHER OPTION THAN A FUND RAISES BUT IMO 75P WOULD PROBABLY BE TOO HIGH. BE INTERESTING TO SEE THE AMOUNT THEY DECIDE TO RAISE." I was going to reassess my position here before year end but considering the latest news there is obviously no point in making any move any time soon, my best option is to carry on buying on any pull back whenever they will occur... GLA
starboard14
25/10/2020
13:03
Am I??I'm just raising some viable questions.I'd love this to be valued at 2 billion.But think at the moment comparisons with Seres a little unrealistic. That's all.Any way I'm long and strong and looking to build a position here.Peace out.
rastamouse
25/10/2020
13:01
I think there are a few recent additions to the BB who are not invested, have no intention of investing and are here sow doubt, noting more. I think we all know who they are. You will see their there names on other BB doing exactly the same thing. Best ignored IMHO, engagement only encourages them. All a bit sad really
trotterstrading
25/10/2020
13:01
I am doing the research and raising viable questions.The slides all look very nice but don't result in valuation comparisons with Seres.Currently IMO DDDD is near fair valuation (USD 225 million).As product viability is proven then an increase in valuation is fair.Some here assume that a simple listing on the Nasdaq will equate to significantly higher share price.Not true and caution required.
rastamouse
Chat Pages: Latest  516  515  514  513  512  511  510  509  508  507  506  505  Older
ADVFN Advertorial
Your Recent History
LSE
DDDD
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210619 18:37:31